Skip to main content
. 2021 May 21;27(19):2281–2298. doi: 10.3748/wjg.v27.i19.2281

Figure 1.

Figure 1

Treatment recommendations based on liver fibrosis severity in metabolic dysfunction-associated fatty liver disease patients. HCC: Hepatocellular carcinoma; MAFLD: Metabolic dysfunction-associated fatty liver disease; NASH: Non-alcoholic steatohepatitis.